Raloxifene
- Generic Name
- Raloxifene
- Brand Names
- Evista, Optruma, Raloxifene Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27NO4S
- CAS Number
- 84449-90-1
- Unique Ingredient Identifier
- YX9162EO3I
- Background
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...
- Indication
Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
- Associated Conditions
- Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment
- Associated Therapies
- -
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT01050842
- Locations
- 🇺🇸
Mayo Clinic In Arizona, Scottsdale, Arizona, United States
Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2009-12-31
- Lead Sponsor
- Fundació Sant Joan de Déu
- Target Recruit Count
- 34
- Registration Number
- NCT01041092
- Locations
- 🇪🇸
Fundació Sant Joan de Déu, Esplugues de Llobregat, Spain
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT00790101
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Cognition in the Study of Tamoxifen and Raloxifene
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 1498
- Registration Number
- NCT00687102
- Locations
- 🇺🇸
The Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States
🇺🇸CCOP Columbus, Columbus, Ohio, United States
🇺🇸Montana Cancer Consortium, Billings, Montana, United States
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 3544
- Registration Number
- NCT00675688
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2008-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7705
- Registration Number
- NCT00670319
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London Bridge, United Kingdom
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 147
- Registration Number
- NCT00532246
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Walnut Creek, California, United States
Long Term Effects of Raloxifene Treatment on Bone Quality
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT00532428
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00431444
- Locations
- 🇺🇸
Women's Health Research, Phoenix, Arizona, United States
🇺🇸Alegent Health, Omaha, Nebraska, United States
🇺🇸UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.